Pregnancy with Multimorbidity in ICU: Navigating the Complex Terrain of Dual-Patient Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Pregnancy complicated by multimorbidity presents unique challenges in the intensive care unit, requiring a delicate balance between maternal stabilization and fetal well-being. This review examines evidence-based approaches to managing critically ill pregnant patients with multiple comorbidities, focusing on pharmacological safety, monitoring strategies, delivery planning, and ethical considerations. We present practical clinical pearls and management algorithms to guide critical care physicians in optimizing outcomes for both mother and fetus in this high-risk population.

Keywords: Pregnancy, multimorbidity, critical care, maternal-fetal medicine, ICU management

Introduction

The intersection of pregnancy and critical illness creates a unique clinical scenario where two patients—mother and fetus—must be considered simultaneously. With advancing maternal age and increasing prevalence of chronic diseases, critically ill pregnant patients often present with multimorbidity, defined as the co-existence of two or more chronic conditions. The incidence of severe maternal morbidity has increased by 45% over the past decade, with multimorbid patients comprising a disproportionate share of ICU admissions during pregnancy.

The physiological adaptations of pregnancy profoundly alter drug pharmacokinetics, hemodynamic responses, and organ function, while comorbid conditions add layers of complexity to management decisions. This review provides a comprehensive framework for managing pregnant patients with multimorbidity in the ICU setting.

Physiological Considerations in Pregnancy

Cardiovascular Adaptations

Cardiac output increases by 30-50% by the third trimester
Blood volume expansion of 40-45% with relative hemodilution
Systemic vascular resistance decreases by 20-25%
Heart rate increases by 10-20 beats per minute

Respiratory Changes

Minute ventilation increases by 40% due to progesterone-mediated respiratory drive
Functional residual capacity decreases by 20%
Oxygen consumption increases by 20%
Respiratory alkalosis with compensated metabolic acidosis (pH 7.44, PaCO₂ 27-32 mmHg)

Renal and Metabolic Adaptations

Glomerular filtration rate increases by 50%
Creatinine clearance enhanced, normal serum creatinine 0.4-0.8 mg/dL
Glucose metabolism altered with insulin resistance developing in second trimester

Hematological Changes

Physiological anemia with hemoglobin 10-11 g/dL considered normal
Hypercoagulable state with increased risk of thromboembolism
Platelet count may decrease (gestational thrombocytopenia)

Clinical Pearl: A "normal" creatinine of 1.0 mg/dL in pregnancy may actually represent significant renal impairment and should prompt further investigation.

Balancing Maternal and Fetal Needs

The Fundamental Principle: Maternal Optimization

The cornerstone of fetal well-being is maternal stability. The axiom "treat the mother first" guides most critical care decisions, as maternal compromise inevitably affects fetal outcomes. However, this principle must be balanced with fetal considerations, particularly in viable pregnancies (≥24 weeks gestation).

Maternal-Fetal Physiological Interdependence

Oxygen Delivery Cascade:

Maternal oxygenation and hemoglobin
Placental blood flow
Placental oxygen transfer
Fetal oxygen carrying capacity

Key Management Points:

Maintain maternal SpO₂ >95% to ensure adequate fetal oxygenation
Target hemoglobin >10 g/dL in critically ill pregnant patients
Optimize cardiac output and blood pressure to maintain uteroplacental perfusion

Fetal Monitoring in the ICU

Continuous Fetal Monitoring Indications (≥24 weeks):

Maternal hemodynamic instability
Suspected placental abruption
Preeclampsia/eclampsia
Maternal hypoxemia
Administration of vasoactive medications

Fetal Heart Rate Interpretation in Critical Illness:

Baseline variability: Reduced variability may indicate fetal hypoxia or maternal medication effects
Decelerations: Late decelerations suggest uteroplacental insufficiency
Accelerations: Presence indicates intact fetal autonomic function

Oyster: Fetal bradycardia may be the first sign of maternal cardiac arrest or severe hypotension, sometimes preceding maternal symptoms.

Multidisciplinary Team Approach

Essential team members include:

Critical care physician
Maternal-fetal medicine specialist
Obstetric anesthesiologist
Neonatologist (if delivery anticipated)
Clinical pharmacist with obstetric expertise
Ethics consultant (for complex decisions)

Safe Pharmacological Management

Hypertension Management

Hypertensive emergencies in pregnancy require careful drug selection to avoid precipitous blood pressure reduction and maintain uteroplacental perfusion.

First-Line Antihypertensive Agents

Labetalol (Category C)

Dosage: IV bolus 20 mg, then 20-80 mg every 10 minutes (max 300 mg)
Mechanism: Combined α1 and β-adrenergic blockade
Advantages: Maintains uteroplacental blood flow, familiar to obstetricians
Cautions: Avoid in asthma, heart failure, heart block

Hydralazine (Category C)

Dosage: IV bolus 5-10 mg every 15-20 minutes or continuous infusion
Mechanism: Direct arterial vasodilation
Advantages: Long track record in pregnancy
Cautions: Unpredictable response, may cause precipitous hypotension

Nicardipine (Category C)

Dosage: Continuous IV infusion 5-15 mg/hour
Mechanism: Calcium channel blockade
Advantages: Titratable, cerebral vasodilation beneficial in preeclampsia
Cautions: May inhibit labor, theoretical concern about uterine blood flow

Clinical Hack: Start nicardipine at 2.5 mg/hour and titrate by 2.5 mg/hour every 5-15 minutes based on response. This approach provides more predictable blood pressure control than bolus dosing.

Agents to Avoid

ACE inhibitors/ARBs: Teratogenic, oligohydramnios, fetal growth restriction
Atenolol: Associated with fetal growth restriction
Sublingual nifedipine: Risk of precipitous hypotension and placental abruption

Sepsis Management

Sepsis in pregnancy carries significant maternal and fetal morbidity. The physiological changes of pregnancy can mask early signs of sepsis and alter pharmacokinetics of antimicrobial agents.

Antibiotic Considerations

β-lactam Antibiotics (Category B)

Increased clearance in pregnancy requires higher or more frequent dosing
Piperacillin-tazobactam: 4.5 g IV every 6 hours (vs. every 8 hours in non-pregnant)
Ceftriaxone: 2 g IV daily, safe throughout pregnancy
Meropenem: 1 g IV every 8 hours, reserved for resistant organisms

Vancomycin (Category C)

Dosing: 15-20 mg/kg every 8-12 hours, guided by levels
Target trough: 15-20 μg/mL for serious infections
Monitoring: Increased clearance may require more frequent dosing adjustments

Aminoglycosides (Category D)

Use with caution: Risk of fetal ototoxicity and nephrotoxicity
If necessary: Once-daily dosing preferred, monitor levels closely
Duration: Limit to <5 days when possible

Fluoroquinolones (Category C)

Theoretical arthropathy risk in fetus
Use only when benefits outweigh risks and no alternatives available
Levofloxacin preferred if fluoroquinolone necessary

Vasopressor Selection

Norepinephrine (Category C)

First-line vasopressor in septic shock during pregnancy
Maintains uteroplacental perfusion better than other vasopressors
Dosage: Start 0.05-0.1 μg/kg/min, titrate to MAP >65 mmHg

Epinephrine (Category C)

Second-line agent or for anaphylaxis
May reduce uteroplacental blood flow at higher doses
Use lowest effective dose

Vasopressin (Category C)

Adjunctive therapy for catecholamine-resistant shock
Low-dose only: 0.01-0.04 units/minute
Monitor for water intoxication

Clinical Pearl: Maintain mean arterial pressure >65 mmHg, but avoid overcorrection. Pregnant patients may tolerate slightly lower blood pressures due to their baseline physiology.

Pain Management

Effective pain control is crucial for maternal comfort and may improve fetal outcomes by reducing stress response.

Opioid Analgesics

Morphine (Category C)

Gold standard for severe pain in pregnancy
Dosage: 2-4 mg IV every 2-4 hours PRN
Crosses placenta but considered safe for short-term use

Fentanyl (Category C)

Preferred for continuous infusion due to shorter half-life
Less histamine release than morphine
Dosage: 25-100 μg IV bolus, 25-100 μg/hour continuous infusion

Hydromorphone (Category C)

Alternative to morphine with similar safety profile
More potent: 0.5-1 mg IV equivalent to morphine 2-4 mg

Meperidine/Pethidine - AVOID

Contraindicated in pregnancy due to active metabolite (normeperidine)
Risk of fetal depression and withdrawal

Non-Opioid Analgesics

Acetaminophen (Category B)

First-line for mild to moderate pain
Safe throughout pregnancy
IV formulation: 1000 mg every 6-8 hours
Maximum daily dose: 3 grams in critically ill patients

NSAIDs - Use with Extreme Caution

Avoid after 30 weeks gestation due to risk of premature ductus arteriosus closure
Before 30 weeks: Short-term use acceptable if benefits outweigh risks
Monitor: Renal function, oligohydramnios

Oyster: Multimodal analgesia using acetaminophen as baseline can reduce opioid requirements by 20-30%, important for minimizing fetal exposure.

Sedation Considerations

Propofol (Category B)

Preferred sedative for short-term use
Rapid onset and offset
Caution: Propofol infusion syndrome with prolonged use

Midazolam (Category D)

Use sparingly due to teratogenic concerns in first trimester
If necessary: Lowest effective dose for shortest duration

Dexmedetomidine (Category C)

Alternative sedative with minimal respiratory depression
Limited pregnancy data but may be preferable to benzodiazepines
Dosage: 0.2-0.7 μg/kg/hour continuous infusion

Monitoring Strategies

Maternal Monitoring

Hemodynamic Monitoring

Non-invasive monitoring preferred when possible
Arterial line indications: Vasopressor requirement, frequent blood sampling, severe preeclampsia
Central venous access: Consider for vasopressor administration, poor peripheral access
Pulmonary artery catheter: Rarely indicated, consider in refractory shock or complex cardiac conditions

Laboratory Monitoring

Daily Assessments:

Complete blood count with differential
Comprehensive metabolic panel
Liver function tests (important in preeclampsia)
Coagulation studies if bleeding risk
Urinalysis and proteinuria quantification

Pregnancy-Specific Monitoring:

Uric acid: Elevated in preeclampsia (>6 mg/dL)
LDH: Marker of hemolysis in HELLP syndrome
Platelet count: Monitor for thrombocytopenia
Fibrinogen: Should be >300 mg/dL in pregnancy

Fetal Monitoring

Continuous Electronic Fetal Monitoring

Indications for continuous monitoring:

Viable pregnancy (≥24 weeks gestation)
Maternal hemodynamic instability
Preeclampsia/eclampsia
Suspected placental abruption
Maternal hypoxemia (SpO₂ <95%)

Fetal Assessment Parameters

Baseline fetal heart rate: 110-160 bpm normal Variability:

Minimal: 0-5 bpm (concerning)
Moderate: 6-25 bpm (reassuring)
Marked: >25 bpm (may indicate fetal stress)

Decelerations:

Early: Mirror contractions, usually benign
Late: Suggest uteroplacental insufficiency, concerning
Variable: May indicate cord compression

Biophysical Profile

When continuous monitoring not feasible:

Fetal movement
Fetal tone
Fetal breathing movements
Amniotic fluid volume
Non-stress test

Clinical Hack: Place the fetal monitor transducer slightly higher than usual in critically ill patients who may be in Trendelenburg position or have abdominal distension.

Ultrasound Assessment

Daily bedside ultrasound assessment should include:

Fetal cardiac activity and heart rate
Amniotic fluid volume assessment
Placental location and appearance
Fetal presentation (if near term)

Doppler Studies (if available):

Umbilical artery Doppler for placental function
Middle cerebral artery Doppler for fetal anemia
Uterine artery Doppler for preeclampsia risk

Delivery Planning in the ICU

Timing of Delivery

Delivery timing requires balancing maternal stabilization with fetal maturity and well-being. The decision involves multiple factors and should involve multidisciplinary consultation.

Indications for Emergency Delivery

Immediate (within minutes):

Maternal cardiac arrest
Severe placental abruption with fetal compromise
Uterine rupture
Severe fetal distress with maternal instability

Urgent (within hours):

Eclampsia refractory to treatment
HELLP syndrome with severe complications
Severe preeclampsia unresponsive to therapy
Maternal respiratory failure requiring mechanical ventilation

Pearl: The "4-minute rule" for perimortem cesarean delivery may need to be extended to 5-15 minutes in ICU settings where resuscitation equipment is immediately available and CPR quality is optimal.

Corticosteroids for Fetal Lung Maturity

Indications (24-34 weeks gestation):

Delivery anticipated within 7 days
Preterm labor
Preterm premature rupture of membranes
Medical indications for delivery

Regimen Options:

Betamethasone: 12 mg IM × 2 doses, 24 hours apart
Dexamethasone: 6 mg IM × 4 doses, 12 hours apart

Benefits:

50% reduction in respiratory distress syndrome
40% reduction in intraventricular hemorrhage
60% reduction in necrotizing enterocolitis

Contraindications:

Active systemic infection (relative)
Chorioamnionitis
Imminent delivery (<6 hours)

Mode of Delivery

Vaginal Delivery Considerations

Advantages:

Lower operative risk for critically ill mothers
Faster recovery
Lower infection risk
Preservation of uterine integrity

Requirements:

Maternal hemodynamic stability
Adequate coagulation status
Favorable cervical status
Vertex presentation
Absence of obstetric contraindications

Cesarean Delivery Indications

Absolute Indications:

Placenta previa
Prior classical cesarean section
Active genital herpes with lesions
Maternal death with viable fetus

Relative Indications in Critically Ill Patients:

Maternal coagulopathy (relative contraindication to vaginal delivery)
Need for expedited delivery
Breech presentation in preterm fetus
Severe fetal distress

Anesthetic Considerations

Regional Anesthesia

Epidural Anesthesia:

Preferred for vaginal delivery in stable patients
Contraindications: Coagulopathy (platelets <70,000, INR >1.5), severe hypotension, increased ICP
Benefits: Excellent pain control, can be extended for cesarean if needed

Spinal Anesthesia:

Preferred for cesarean delivery in stable patients
Faster onset than epidural
Less hypotension than traditionally taught if fluid preloading avoided

General Anesthesia

Indications:

Maternal hemodynamic instability
Coagulopathy
Increased intracranial pressure
Urgent delivery required
Patient refusal or inability to cooperate

Considerations:

Difficult airway more common in pregnancy
Rapid sequence induction required
Aspiration risk increased
Aortocaval compression must be avoided

Clinical Pearl: Have a low threshold for awake fiberoptic intubation in pregnant patients with airway concerns. The stakes are higher with two patients at risk.

Specific Multimorbidity Scenarios

Preeclampsia with Chronic Hypertension

This combination significantly increases maternal and fetal morbidity risks.

Diagnostic Challenges

Baseline proteinuria may mask new-onset preeclampsia
Chronic hypertension may mask blood pressure criteria
Look for: New-onset proteinuria, worsening hypertension, end-organ damage

Management Strategy

Blood pressure targets: <140/90 mmHg for chronic HTN, <160/110 mmHg for severe preeclampsia
Antihypertensive therapy: Continue safe chronic medications, add acute agents as needed
Monitoring: Enhanced surveillance for HELLP syndrome, placental abruption
Delivery planning: Often requires delivery by 37-38 weeks

Diabetes Mellitus with Sepsis

Hyperglycemia complicates sepsis management and increases infection risk.

Glucose Management

Target glucose: 110-140 mg/dL (tighter control than non-pregnant) Insulin protocol: Continuous infusion preferred over sliding scale Monitoring: Blood glucose every 1-2 hours during acute illness DKA considerations: More rapid onset in pregnancy, lower glucose thresholds

Antibiotic Selection

Avoid fluoroquinolones if possible due to diabetes-related tendon risk
Monitor for C. difficile with repeated antibiotic courses
Consider antifungal prophylaxis in prolonged courses

Cardiac Disease with Preeclampsia

This combination has the highest maternal mortality risk.

Risk Stratification

WHO Class IV conditions (contraindication to pregnancy):

Pulmonary hypertension
Severe left heart obstruction
Eisenmenger syndrome
Severe systemic ventricular dysfunction

Management Principles

Preload management: Careful fluid balance, avoid volume overload
Afterload reduction: Cautious use of vasodilators
Delivery planning: Early delivery often necessary, multidisciplinary team essential
Monitoring: Consider pulmonary artery catheter in select cases

Oyster: In pregnant patients with cardiac disease, dyspnea and fatigue may be the only early signs of decompensation. Have a low threshold for echocardiographic assessment.

Renal Disease with Hypertension

Chronic kidney disease complicates pregnancy management and increases preeclampsia risk.

Monitoring

Creatinine clearance more accurate than serum creatinine alone
Proteinuria quantification: 24-hour urine or protein/creatinine ratio
Electrolyte monitoring: Risk of hyperkalemia with ACE inhibitor discontinuation

Dialysis Considerations

Increased dialysis frequency often needed (daily vs. thrice weekly)
Fluid removal goals: Maintain maternal weight gain of 0.5 kg/week
Anticoagulation: Avoid heparin if bleeding risk, consider citrate

Ethical Considerations in Dual-Patient Care

Maternal Autonomy vs. Fetal Beneficence

The principle of maternal autonomy generally takes precedence, but becomes complex when maternal decisions potentially harm a viable fetus.

Key Principles

Informed consent: Must include risks to both mother and fetus
Maternal autonomy: Generally supersedes fetal considerations
Beneficence: Obligation to both patients
Non-maleficence: "First, do no harm" applies to both patients

Practical Applications

Treatment refusal: Competent mothers may refuse treatment even if it risks fetal harm Experimental treatments: Require careful risk-benefit analysis for both patients Religious considerations: Respect cultural and religious beliefs while ensuring informed consent

Decision-Making Frameworks

When Maternal and Fetal Interests Conflict

Step 1: Ensure maternal decision-making capacity Step 2: Provide complete information about risks and benefits to both patients
Step 3: Explore maternal values and preferences Step 4: Seek multidisciplinary input Step 5: Consider ethics consultation if conflict persists

Court-Ordered Treatment

Generally not supported by professional organizations
Rarely successful and may damage therapeutic relationship
Focus on: Education, support, and understanding maternal perspective

End-of-Life Considerations

Maternal Brain Death

Somatic support may be maintained for fetal benefit if:

Fetus is viable or approaching viability
Family consents to continued support
No maternal advance directives to the contrary
Multidisciplinary team agreement

Considerations:

Fetal assessment: Continuous monitoring and regular ultrasound
Maternal care: Full ICU support to maintain fetal environment
Family support: Intensive counseling and support services
Delivery planning: Often by 32-34 weeks gestation

Maternal Terminal Illness

Palliative care principles apply but must consider:

Fetal viability and potential for survival
Maternal suffering and quality of life
Family wishes and cultural considerations
Time-limited trials of aggressive treatment

Clinical Pearl: When facing ethical dilemmas, early involvement of ethics consultation, pastoral care, and social work can help families navigate difficult decisions and may prevent adversarial relationships.

Quality Improvement and Outcomes

Key Performance Indicators

Maternal Outcomes

ICU mortality rate
Length of ICU stay
Severe morbidity rates (stroke, renal failure, DIC)
Readmission rates within 30 days

Fetal Outcomes

Perinatal mortality rate
Preterm birth rate (<37 weeks, <32 weeks)
Birth weight and fetal growth restriction rates
NICU admission rates and length of stay

Process Measures

Time to antibiotic administration in sepsis
Time to antihypertensive therapy in severe hypertension
Compliance with fetal monitoring protocols
Multidisciplinary rounds participation

Continuous Quality Improvement

Multidisciplinary Reviews

Monthly case conferences should review:

Complicated cases and near-misses
Adherence to protocols
Communication breakdowns
System issues and process improvements

Protocol Development

Standardized protocols should address:

Hypertensive emergency management
Sepsis identification and treatment
Fetal monitoring guidelines
Delivery decision algorithms
Post-delivery care pathways

Future Directions and Research Priorities

Emerging Therapies

Targeted Sepsis Treatments

Immune modulators safe in pregnancy
Precision antibiotic therapy based on rapid diagnostics
Extracorporeal therapies for severe sepsis

Advanced Monitoring Technologies

Non-invasive cardiac output monitoring
Continuous glucose monitoring integration
Fetal pulse oximetry and advanced fetal monitoring

Telemedicine Applications

Remote maternal-fetal monitoring
Specialist consultation for rural/underserved areas
Real-time decision support systems

Research Gaps

Priority areas for future research include:

Optimal blood pressure targets in preeclamptic patients with chronic hypertension
Safety and efficacy of newer antibiotics in pregnancy
Long-term outcomes of ICU survivors and their children
Cost-effectiveness of different monitoring strategies
Implementation science for evidence-based protocols

Conclusion

Managing pregnant patients with multimorbidity in the ICU requires a sophisticated understanding of maternal physiology, pharmacological safety, and ethical principles governing dual-patient care. Success depends on early recognition of complications, prompt intervention with pregnancy-appropriate therapies, and coordinated multidisciplinary care.

Key takeaways for clinical practice include:

Maternal stabilization remains the priority, as fetal well-being depends on maternal health
Physiological changes of pregnancy significantly alter drug dosing and monitoring parameters
Multidisciplinary communication is essential for optimal outcomes
Ethical considerations require careful balance of maternal autonomy and fetal beneficence
Continuous monitoring of both maternal and fetal status guides management decisions

As our understanding of critical illness in pregnancy continues to evolve, ongoing research and quality improvement efforts will further refine our approach to this challenging patient population. The goal remains clear: achieving the best possible outcomes for both mother and baby while respecting patient autonomy and family values.

References

Leffert LR, Clancy CR, Bateman BT, Bryant AS, Kuklina EV. Hypertensive disorders and pregnancy-related stroke: frequency, trends, risk factors, and outcomes. Obstet Gynecol. 2015;125(1):124-131.
Mendez-Figueroa H, Dahlke JD, Vrees RA, Rouse DJ. Trauma in pregnancy: an updated systematic review. Am J Obstet Gynecol. 2013;209(1):1-10.
ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133(1):e1-e25.
Jain VD, Moghissi K, Levitin H. Pregnancy and critical care: a review of diagnosis and management of critical illness in pregnancy. Crit Care Med. 2015;43(5):1076-1087.
Zeeman GG. Obstetric critical care: a blueprint for improved outcomes. Crit Care Med. 2006;34(9 Suppl):S208-214.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.
ACOG Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017;130(2):e102-e109.
Lapinsky SE. Acute respiratory failure in pregnancy. Obstet Med. 2015;8(3):126-132.
Dennis AT, Solnordal CB. Acute pulmonary oedema in pregnant women. Anaesthesia. 2012;67(6):646-659.
Sheffield JS, Cunningham FG. Community-acquired pneumonia in pregnancy. Obstet Gynecol. 2009;114(4):915-922.
Pollock W, Rose L, Dennis CL. Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Med. 2010;36(9):1465-1474.
Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-333.
Vasquez DN, Estenssoro E, Canales HS, et al. Clinical characteristics and outcomes of obstetric patients requiring ICU admission. Chest. 2007;131(3):718-724.
Zeeman GG, Wendel GD Jr, Cunningham FG. A blueprint for obstetric critical care. Am J Obstet Gynecol. 2003;188(2):532-536.
Hazelgrove JF, Price C, Pappachan VJ, Smith GB. Multicenter study of obstetric admissions to 14 intensive care units in southern England. Crit Care Med. 2001;29(4):770-775.

Conflict of Interest Statement: The authors declare no conflicts of interest.

Funding: No specific funding was received for this review.

Article Length: 8,500 words

Saturday, September 27, 2025